<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748186</url>
  </required_header>
  <id_info>
    <org_study_id>STRO-002-GM1</org_study_id>
    <nct_id>NCT03748186</nct_id>
  </id_info>
  <brief_title>Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian &amp; Endometrial Cancers</brief_title>
  <official_title>A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutro Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutro Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002&#xD;
      given intravenously every 3 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 1, open-label, multicenter, dose-escalation study with dose expansion&#xD;
      to identify the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and to&#xD;
      evaluate the safety, tolerability, and preliminary antitumor activity of STRO-002 in adult&#xD;
      subjects with advanced epithelial ovarian cancer (EOC), including fallopian or primary&#xD;
      peritoneal cancer, and endometrial cancer. Fallopian tube and primary peritoneal cancers are&#xD;
      treated in the same manner as epithelial ovarian cancers and are thus included in this phase&#xD;
      1 study. Subjects enrolled in the study will be required to have progressive or recurrent&#xD;
      disease after standard approved therapy as defined in the study eligibility criteria. The&#xD;
      study has completed dose escalation and is currently in dose expansion, enrolling endometrial&#xD;
      and ovarian cancer subjects.&#xD;
&#xD;
      All subjects enrolled on the study are required to have tumor tissue for determining folate&#xD;
      receptor alpha (FolRα) expression levels, either from a prior surgery or tumor biopsy or from&#xD;
      a biopsy performed during study screening. The testing for FolRα is done via an ICH assay. A&#xD;
      minimum level of FolRα expression is required for enrollment for endometrial cancer but not&#xD;
      for ovarian cancer.&#xD;
&#xD;
      Study drug, STRO-002, is administered by intravenous (IV) infusion on day 1 of 21-day cycles.&#xD;
      Clinical evaluations and/or laboratory tests will be performed at a pre-specified&#xD;
      schedule-weekly for cycles 1-4, and at the beginning of every cycle starting with cycle 5 as&#xD;
      described in the schedule of assessments. Samples for PK analysis will occur at specific&#xD;
      times on days 1, 8, and 15 of cycles 1 and 4, Day 1 of cycles 2, 3, and 5 and at the end of&#xD;
      treatment (EOT) visit. The study requires imaging with a CT or MRI scan of the chest abdomen&#xD;
      and pelvis at screening, every 6 weeks after enrollment for the first 18 weeks, then every 9&#xD;
      weeks, and at the end of treatment (EOT) visit. Additional X-rays may be required to confirm&#xD;
      disease responses and per local institution standard of care.&#xD;
&#xD;
      Additional clinical evaluations and lab testing may occur at the discretion of the&#xD;
      investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study is a modified 3+3 dose escalation study with a dose expansion. Dose escalation is in advanced ovarian cancer patients with relapsed or refractory disease to standard approved therapy. Dose expansion includes 2 cancer populations, ovarian cancer and endometrial cancer. The ovarian cancer expansion cohort (Cohort A) is a dose ranging design with randomization into 2 dose levels of STRO-002, 4.3 mg/kg and 5.2 mg/kg. Dose expansion in endometrial cancer (Cohort B) is a single dose cohort design, STRO-002 5.2 mg/kg. Endometrial subjects with prior pelvic irradiation will start treatment of STRO-002 at 4.3 mg/kg with step up to 5.2 mg/kg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)</measure>
    <time_frame>18 months</time_frame>
    <description>Incidence of adverse events (AEs) observed across STRO-002 dose levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Define the recommended phase 2 dose (RP2D) of STRO-002</measure>
    <time_frame>18 months</time_frame>
    <description>Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Define the maximum tolerated dose (MTD) of STRO-002</measure>
    <time_frame>18 months</time_frame>
    <description>Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Evaluate preliminary anti-tumor activity (ovarian, Fallopian and primary peritoneal cancer patients)</measure>
    <time_frame>24 months</time_frame>
    <description>Objective response rate per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Evaluate preliminary anti-tumor activity (endometrial cancer patients)</measure>
    <time_frame>24 months</time_frame>
    <description>Objective response rate per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax)</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of maximum plasma concentration after the administration of STRO-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Characterize the PK of STRO-002 by measuring the half-life (t1/2) of STRO-002</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of terminal half-life of STRO-002 after the administration of STRO-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Characterize the PK of STRO-002 measuring the total area under the concentration versus time curve from zero to infinity (AUCinf)</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of AUC to infinity (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Characterize the PK of STRO-002 by measuring the clearance (CL)</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Characterize the PK of STRO-002 by measuring the the steady state volume of distribution (Vss)</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of steady state volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Assess the formulation of anti-drug antibodies to STRO-002</measure>
    <time_frame>18 months</time_frame>
    <description>Circulating anti-drug antibodies (ADAs) formed to STRO-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Further evaluate the incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with abnormal laboratory values and/or adverse events related to STRO-002 treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of duration of response (DOR) in patients treated with STRO-002</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of response per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of progression-free survival (PFS) in patients treated with STRO-002</measure>
    <time_frame>24 months</time_frame>
    <description>Progression-free survival per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Evaluate preliminary effect of STRO-002 treatment on CA-125 levels</measure>
    <time_frame>24 months</time_frame>
    <description>Response assessment based on the Gynecologic Cancer Intergroup (GCIG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Characterize the PK of STRO-002 by measuring the maximum plasma concentration (Cmax)</measure>
    <time_frame>24 months</time_frame>
    <description>Measurement of maximum plasma concentration (Cmax) after the administration of STRO-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>24 months</time_frame>
    <description>Measurement of AUC to infinity (AUC inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Characterize the PK of STRO-002 by measuring the clearance (CL)</measure>
    <time_frame>24 months</time_frame>
    <description>Measurement of total body clearance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Part 1: Preliminary assessment of the anti-tumor activity of STRO-002</measure>
    <time_frame>18 months</time_frame>
    <description>Objective response rate per RECIST 1.1</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Ovary Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Endometrioid Adenocarcinoma</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>STRO-002 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: STRO-002 at increasing dose levels&#xD;
Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STRO-002</intervention_name>
    <description>intravenous antibody drug conjugate</description>
    <arm_group_label>STRO-002 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Measurable disease per RECIST 1.1&#xD;
&#xD;
          3. ECOG performance status (0-1)&#xD;
&#xD;
          4. Life expectancy &gt; 3 months&#xD;
&#xD;
          5. Pathological confirmation of disease under study (historical information, diagnosis,&#xD;
             pathology report, etc)&#xD;
&#xD;
               1. Expansion Cohort A: High-grade serous EOC, fallopian tube cancer or primary&#xD;
                  peritoneal cancer&#xD;
&#xD;
               2. Expansion Cohort B: Histologically diagnosed epithelial endometrial cancer&#xD;
                  (endometrioid and serous adenocarcinomas; undifferentiated carcinoma; mixed&#xD;
                  epithelial carcinoma; or adenocarcinoma NOS)&#xD;
&#xD;
          6. Relapsed and/or progressive disease&#xD;
&#xD;
               1. Dose Expansion Cohort A (Ovarian Cancer):&#xD;
&#xD;
                    -  Platinum resistant and received 1-3 prior regimens or&#xD;
&#xD;
                    -  Platinum sensitive and either:&#xD;
&#xD;
                    -  Progressed after 2 prior lines of platinum therapy (regardless of platinum&#xD;
                       status)and received 2-3 prior regimens or&#xD;
&#xD;
                    -  Progressed after 1 line of platinum therapy and 1 line of non-platinum&#xD;
                       therapy and received a total of 2-3 prior regimens if contraindicated to&#xD;
                       receive second platinum regimen.&#xD;
&#xD;
               2. Dose Expansion Cohort B (Endometrial Cancer):&#xD;
&#xD;
                    -  Relapsed or progression after at least 1 platinum-based chemotherapy regimen&#xD;
                       or 1 immunotherapy-based regimen but not to exceed more than 3 prior&#xD;
                       regimens.&#xD;
&#xD;
          7. Fresh or archival tumor tissue samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Low grade (grade 1) ovarian carcinoma, clear cell, mucinous and sarcomatous ovarian&#xD;
             carcinomas (Cohort A).&#xD;
&#xD;
          2. Endometrial carcinosarcomas, leiomyosarcoma and stromal sarcomas (Cohort B).&#xD;
&#xD;
          3. Prior treatment with a FolRα-targeting ADCs or FolRα-targeting vaccines&#xD;
&#xD;
          4. Platinum-refractory during frontline treatment (Cohort A)&#xD;
&#xD;
          5. Greater than 3 lines of prior treatment&#xD;
&#xD;
          6. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or&#xD;
             to antibody-related fusion protein treatment&#xD;
&#xD;
          7. Preexisting clinically significant ocular disorders, clinically significant&#xD;
             pre-exisiting ocular disorders, severe chronic obstructive pulmonary disease or&#xD;
             asthma, clinically significant cardiac or cerebrovascular disease, or other&#xD;
             significant concurrent, uncontrolled medical condition&#xD;
&#xD;
          8. Metastatic central nervous system or meningeal disease&#xD;
&#xD;
          9. Concurrent participation in another therapeutic treatment trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients are required to have ovarian, fallopian, primary peritoneal or endometrial cancer.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Molina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sutro Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Berman, MD</last_name>
    <phone>650-801-6417</phone>
    <email>STRO-002ClinDev@sutrobio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Palumbo</last_name>
    <phone>6506764689</phone>
    <email>STRO-002ClinDev@sutrobio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Oncology - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Klinker</last_name>
      <phone>520-269-3821</phone>
      <email>julie.klinker@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Buscema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Gibson, RN, BSN</last_name>
      <phone>303-418-7639</phone>
      <email>Patricia.Gibson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sami Diab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manojkumar Bupathi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Baker, RN, BSN, OCN</last_name>
      <phone>203-785-6398</phone>
      <email>lisa.baker@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Martha Luther</last_name>
      <phone>203-737-2781</phone>
      <email>martha.luther@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Santin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institue, Baptist Health South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Moya, BSCR, CCRP</last_name>
      <phone>786-527-8861</phone>
      <email>IsabelMoy@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>John Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Anderson</last_name>
      <phone>813-974-1806</phone>
      <email>mlander5@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta Oncology</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa James</last_name>
      <phone>706-721-8981</phone>
      <email>mejames@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Sharad Ghamande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hatti Koning</last_name>
      <phone>773-834-5722</phone>
      <email>hkoning@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>John Moroney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <phone>877-664-7724</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Cheryl Aylesworth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Anderson</last_name>
      <phone>612-884-6331</phone>
      <email>lynn.anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Emily Prendergast, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karyn Mianulli, BSN, RN</last_name>
      <phone>702-952-3443</phone>
      <email>karyn.mianulli@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyanka Patel</last_name>
      <email>Priyanka.Patel@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Alison Haegler</last_name>
      <email>Alison.Haegler@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bhavana Pothuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Neagle, RN, BSN</last_name>
      <phone>980-442-2303</phone>
      <email>Heather.Neagle@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>R. Wendel Naumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Vollmer</last_name>
      <phone>513-584-7698</phone>
      <email>cancer@uchealth.com</email>
    </contact>
    <investigator>
      <last_name>Amanda Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University, James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Myers</last_name>
      <phone>614-293-3873</phone>
      <email>Molly.Myers@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>David O'Malley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Rodgriguez</last_name>
      <phone>215-614-0234</phone>
      <email>diegorod@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lainie Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Perez, BS, CCRP</last_name>
      <phone>215-955-6407</phone>
      <email>cynthia.perez@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Russell Schilder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Kueber</last_name>
      <phone>864-455-3774</phone>
      <email>jan.kueber@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeff Edenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheetal Champaneria</last_name>
      <phone>615-329-6875</phone>
      <email>sheetal.champaneria@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <phone>703-208-9268</phone>
      <email>Marcy.Sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest-South Spokane</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carissa Urbat</last_name>
      <phone>509-474-3820</phone>
      <email>Lisa.davis2@providence.org</email>
    </contact>
    <investigator>
      <last_name>Melanie Bergman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suki Skandarajah</last_name>
      <phone>414-805-5337</phone>
      <email>sskandarajah@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Denise Uyar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institut d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Farras Llansana</last_name>
      <phone>(+34)93-489-4158</phone>
      <email>nfarras@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Ana Oaknin Benzaquen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra -Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Gonzalez Martin, MD</last_name>
      <phone>+34913531920</phone>
      <email>agonzalezma@unav.es</email>
    </contact>
    <contact_backup>
      <last_name>Eduardo Castañón, MD</last_name>
      <phone>+34913531920</phone>
      <email>ecastanon@unav.es</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Gonzalez Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Alvarez</last_name>
      <phone>+34 91 727 75 16</phone>
      <email>yolandalapaz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andres Redondo Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro - CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Morgades</last_name>
      <phone>+34 91 756 79 84</phone>
      <phone_ext>4887</phone_ext>
      <email>pmorgades@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Jesus Garcia-Donas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

